|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||||
| Cash | ||||||||||
| Prepaid expenses | ||||||||||
| Total current assets | ||||||||||
| Cash and Investments held in Trust Account | ||||||||||
| Derivative assets - forward purchase agreement | ||||||||||
| Total Assets | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable | ||||||||||
| Accrued expenses | ||||||||||
| Due to related party | ||||||||||
| Note payable - related party | ||||||||||
| Extension loan - related party, at fair value | ||||||||||
| Working capital loans - related party, at fair value | ||||||||||
| Total current liabilities | ||||||||||
| Deferred legal fees | ||||||||||
| Deferred underwriting commissions | ||||||||||
| Derivative liabilities | ||||||||||
| Total Liabilities | ||||||||||
| Class A ordinary shares subject to possible redemption, $0.0001 par value; 25,347,160 and 69,000,000 shares issued and outstanding, at $10.32 and $10.14 per share at March 31, 2023 and December 31, 2022, respectively | ||||||||||
| Shareholders’ Deficit: | ||||||||||
| Class B ordinary shares, $0.0001 par value; 100,000,000 shares authorized; 17,250,000 shares issued and outstanding at March 31, 2023 and December 31, 2022 | ||||||||||
| Additional paid-in capital | ||||||||||
| Accumulated deficit | ||||||||||
| Total shareholders’ deficit | ||||||||||
| Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit |
Loading...
